NEW SITE — FASTER TURNAROUND, MORE LABS. READ ON
Peptide testing

Ordered peptides from Mokemei Zhengzhou Biotechnology MKM? Mail in a sample (US only) and let us test it.

Test my supply
+16 more ↓
61%
Finnrick rating
#431 of 500 ranked vendors
28 of 41 classifiable tests passed
methodology · Purity focus
Finnrick analysis

Mokemei Zhengzhou Biotechnology MKM's purity-focus record is strongest in BPC-157 and Tesamorelin, while Retatrutide and Epithalon define the weaker side. Evidence is recent but uneven and concentrated: Retatrutide stays volatile despite recent passes, Epithalon has repeated failures, and thin records plus labeling caveats keep uncertainty high.

methodology →
vendor intelligence report
Vendor Intelligence Report: Mokemei Zhengzhou Biotechnology MKM

Chinese registry, WHOIS, and export records conflict with MKM's long-history narrative, including a non-peptide cargo trail. The report also maps same-server peptide infrastructure, forum review control, shipping disputes, and a reported HYNH Telegram channel.

22 pages7 risk factors assessed13 Jun 2026
read the report
Peptides
#
Peptide
$/MG
Rating
N
1
Tirzepatide
$0.45
77%
4
2
GHK-Cu
$0.07
76%
7
3
Retatrutide
$0.65
68%
17
4
BPC-157
$0.60
62%
5
5
Tesamorelin
$1.95
55%
3
6
TB-500
$1.50
46%
2
7
Epithalon
$0.45
27%
3
8
5-Amino-1MQ
$0.20
-
0
9
AOD-9604
$1.60
-
0
10
ARA-290
$0.65
-
0
12
CJC-1295
$1.60
-
0
13
Glutathione
$0.01
-
0
14
HGH
$1.59
-
0
15
Ipamorelin
$0.80
-
0
16
Kisspeptin
$1.40
-
0
17
KPV
$0.70
-
0
18
Melanotan II
$0.50
-
0
19
MOTS-c
$0.53
-
0
20
NAD+
$0.02
-
0
21
Pinealon
$0.65
-
0
22
PT-141
-
-
0
23
SS-31
$0.63
-
0
Contact channels
Rating trend
CUMULATIVE FINNRICK RATING
83%+65%+48%+30%+<30%23 Oct 2025: 74%14 Nov 2025: 64%17 Nov 2025: 64%20 Feb 2026: 58%22 Feb 2026: 63%19 Mar 2026: 64%23 Apr 2026: 64%23 Apr 2026: 64%1 Jun 2026: 65%12 Jun 2026: 65%23 Jun 2026: 65%24 Jun 2026: 64%1 Jul 2026: 60%9 Jul 2026: 59%17 Jul 2026: 58%20 Jul 2026: 59%21 Jul 2026: 60%23 Jul 2026: 59%12 Aug 2026: 58%12 Aug 2026: 60%4 Sep 2026: 59%15 Sep 2026: 59%18 Sep 2026: 62%18 Sep 2026: 62%24 Sep 2026: 59%24 Sep 2026: 60%24 Sep 2026: 60%24 Sep 2026: 61%24 Sep 2026: 61%24 Sep 2026: 60%24 Sep 2026: 59%25 Sep 2026: 59%29 Sep 2026: 59%30 Sep 2026: 60%1 Oct 2026: 60%14 Oct 2026: 61%20 Oct 2026: 60%30 Oct 2026: 60%5 Nov 2026: 60%9 Nov 2026: 61%17 Nov 2026: current 61%74%64%61%Oct 25Nov 26
Peptide testing

Ordered peptides from Mokemei Zhengzhou Biotechnology MKM? Mail in a sample (US only) and let us test it.

Test my supply
Mokemei Zhengzhou Biotechnology MKM test history
COA-backed lab tests
1-10 of 41

About Mokemei Zhengzhou Biotechnology MKM test results from Finnrick

Mokemei Zhengzhou Biotechnology MKM is a peptide vendor tracked in Finnrick's independent testing dataset. This page compiles batch-level results across 7 peptides and 41 tests, including ratings, observed price signals, recent test dates, and correction history where available.

Finnrick ratings are calculated from published sample data using the selected rating standard. The default standard evaluates purity, dose accuracy, and label quality, then adjusts low-volume results so small sample counts do not appear more certain than the data supports.

The most visible Mokemei Zhengzhou Biotechnology MKM peptides in this dataset are BPC-157 (5 tests), Epithalon (3 tests) and GHK-Cu (7 tests). Use the peptide table above to compare the current Finnrick rating, price per mg, and sample volume for each peptide.

Recent tests and corrections are shown below when available. Samples may be acquired by Finnrick directly or submitted through Finnrick testing programs; the goal is to make safety and supply-chain evidence easier to evaluate than vendor marketing claims alone. This page currently lists 41 recent tests.

Corrections
No corrections.
Peptide testing

Ordered peptides from Mokemei Zhengzhou Biotechnology MKM? Mail in a sample (US only) and let us test it.

Test my supply